Skip to content

Cancer-Seeking Spikes and SEER Metastatic Rise in Women Under 50

Day 4 · 4:00:08 · Deanna McLeod · Myriam Bohémier · Nicole Sedore

  • 🎗️ OHIP data show breast and uterine cancer health-seeking soaring past confidence limits, especially under age 50.
  • 📋 SEER registry (half of U.S.) confirms extra uptick in metastatic breast, ovarian and cervical cancer at presentation.
  • 🧬 mRNA gene-therapy mechanism was regulated only to lower vaccine safety standards—an unprecedented switch.

Cancer signals and misclassification of platform technology.

← Emergency Rolling Reviews Replaced Proper Safety Testing | Empty Hospitals, Inflated Models and One Official’s Total Control →

Transcript

Deanna McLeod · 4:00:08

And so on the right-hand side— on the left-hand side, sorry, you have on the upper panel, you have breast cancer, and that's greater than 50 years old, and then breast cancer less than 50 years old. And again, we have a trend for an increase in breast cancer. You've got your yellow, you've got your gray confidence intervals, and then the yellow band is the rollout of the mRNA product in 2021. And almost immediately following the rollout, you see that those blue dots start to increase above the gray band. And what that means is that there's more health-seeking behavior for breast cancer now from women older than 50, which is when you expect it. But tragically, on the right-hand panel, you have incredibly elevated health-seeking behavior for breast cancer in younger women, less than 50 years old, well beyond the confidence intervals. So if you look at uterine cancer, that's the panel below that, you have greater than 50, again, off the charts out of the, the regular confidence intervals.

Deanna McLeod · 4:01:15

On the right-hand side, less than 50, again, right off the charts. So I just want to stress that in our exuberance to get a product available for COVID, which was an incredible threat, we classified this mRNA product as a vaccine and we did the safety testing for a vaccine even though the actual mode of action was gene therapy. So a gene therapy, which is an mRNA product, would be what this would be technically classified for in terms of how it works in your body. But the regulatory classification was as a vaccine because it was intended to stimulate immunity or prevent infection. So they actually did this switcheroo and called it a vaccine because of the intention to treat, and that's never been done. And the safety testing therefore was very much lower because they considered it a vaccine rather than gene therapy. I know I gotta go fast.

Myriam Bohémier · 4:02:15

Well, you've got about a minute.

Nicole Sedore · 4:02:16

Sorry.

Deanna McLeod · 4:02:17

Um, so this is cancer registry data. So when you look at healthcare-seeking behavior, you think, okay, what is this? Is this, you know, new cancers? Is it, uh, people whose cancer progressed because we did lockdowns and shut down cancer care? You know, what are we actually looking at? And this is SEER data. SEER data is cancer registry data. It's the, the most reliable population-level data that you can to. This is SEER data in women less than 50 years. And this is women presenting with metastatic cancer. So breast cancer, cervical cancer, uterine cancer, ovarian cancer. And the yellow band is, is the, the COVID period. It's by year. And what you can see over the COVID period, not always beginning in 2021, but in around there, you see this uptick So there's always a trend upwards, but you see an, an extra increase in women with metastatic breast cancer, ovarian cancer, cervical cancer at presentation, meaning that for some reason this cancer is growing very fast.

Deanna McLeod · 4:03:22

This is data that represents half of the US population. It's cancer registry data, which means that it's been validated and confirmed as such. So I just want to— please give me a little bit of time.